Skip to main content

Compare Stocks

Date Range: 

 Fusion PharmaceuticalsSQZ BiotechnologiesOutlook TherapeuticsLineage Cell TherapeuticsOpthea
SymbolNASDAQ:FUSNNYSE:SQZNASDAQ:OTLKNYSEAMERICAN:LCTXNASDAQ:OPT
Price Information
Current Price$8.18$11.88$2.09$2.26$8.12
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.41.71.31.61.5
Analysis Score3.53.53.53.53.4
Community Score2.84.32.83.04.3
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.00.80.0
Earnings & Valuation Score0.00.60.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$23.67$38.33$6.33$5.60$36.00
% Upside from Price Target189.50% upside222.67% upside203.03% upside147.79% upside343.35% upside
Trade Information
Market Cap$347.09 million$331.24 million$362.84 million$365.30 million$352.87 million
BetaN/AN/A0.462.11N/A
Average Volume45,831167,4993,565,8871,651,44011,326
Sales & Book Value
Annual RevenueN/AN/A$8.15 million$3.52 millionN/A
Price / SalesN/AN/A44.52103.78N/A
CashflowN/AN/AN/A$0.17 per shareN/A
Price / CashN/AN/AN/A13.32N/A
Book ValueN/AN/A$0.02 per share$0.74 per shareN/A
Price / BookN/AN/A104.503.05N/A
Profitability
Net Income$-16,190,000.00N/A$-35,240,000.00$-11,710,000.00N/A
EPSN/AN/A($0.67)$0.14N/A
Trailing P/E Ratio0.000.00N/AN/A0.00
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-1,001.59%N/A
Return on Equity (ROE)-26.14%N/AN/A-26.07%N/A
Return on Assets (ROA)-18.26%N/A-148.04%-22.91%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.33%N/AN/A
Current Ratio55.92%N/A1.13%5.13%N/A
Quick Ratio55.92%N/A1.13%5.13%N/A
Ownership Information
Institutional Ownership Percentage61.35%N/A3.04%35.72%N/A
Insider Ownership PercentageN/AN/A4.00%29.00%N/A
Miscellaneous
Employees5198849N/A
Shares Outstanding42.46 million27.88 million173.61 million161.64 million43.46 million
Next Earnings Date8/10/2021 (Estimated)8/10/2021 (Estimated)8/13/2021 (Estimated)8/5/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Opthea (NASDAQ:OPT)  Shares Down 3.6% Opthea (NASDAQ:OPT) Shares Down 3.6%
americanbankingnews.com - May 4 at 12:34 AM
Opthea Company Secretary ResignationOpthea Company Secretary Resignation
finance.yahoo.com - April 6 at 6:18 AM
Why Codan, Evolution, Opthea, & People Infrastructure shares are charging higherWhy Codan, Evolution, Opthea, & People Infrastructure shares are charging higher
fool.com.au - March 14 at 11:29 PM
Why the Opthea (ASX:OPT) share price is soaring 11% todayWhy the Opthea (ASX:OPT) share price is soaring 11% today
msn.com - March 14 at 11:29 PM
Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference Australian Stock Exchange:OPT.AXOpthea to Present at the Oppenheimer 31st Annual Healthcare Conference Australian Stock Exchange:OPT.AX
compsmag.com - March 10 at 1:34 PM
Opthea (ASX:OPT) finalises design for pivotal studiesOpthea (ASX:OPT) finalises design for pivotal studies
themarketherald.com.au - February 24 at 8:19 AM
Opthea Finalizes Study Designs and Start-up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMDOpthea Finalizes Study Designs and Start-up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD
finance.yahoo.com - February 24 at 8:19 AM
Megan Baldwin just joined the board of this ASX biotech stockMegan Baldwin just joined the board of this ASX biotech stock
stockhead.com.au - February 16 at 12:25 AM
Invex Therapeutics appoints biotech expert Dr Megan Baldwin to its boardInvex Therapeutics appoints biotech expert Dr Megan Baldwin to its board
smallcaps.com.au - February 16 at 12:25 AM
Clinical Trials Tracker: 2022 and beyondClinical Trials Tracker: 2022 and beyond
msn.com - January 29 at 8:08 PM
Capital raising hits new highCapital raising hits new high
miragenews.com - January 19 at 5:35 PM
News for Opthea Ltd (spons. ADRs)News for Opthea Ltd (spons. ADRs)
markets.businessinsider.com - January 4 at 12:57 AM
Opthea Limited (OPT)Opthea Limited (OPT)
ca.finance.yahoo.com - December 18 at 12:46 AM
Opthea Limited American Depositary Shares (OPT)Opthea Limited American Depositary Shares (OPT)
nasdaq.com - December 17 at 7:46 PM
Opthea Limited - American Depositary SharesOpthea Limited - American Depositary Shares
benzinga.com - December 17 at 7:46 PM
Opthea Ltd.Opthea Ltd.
barrons.com - December 17 at 7:46 PM
Opthea LtdOpthea Ltd
bloomberg.com - November 22 at 12:08 AM
DateCompanyBrokerageAction
4/13/2021Fusion PharmaceuticalsMorgan StanleyLower Price Target
12/17/2020Fusion PharmaceuticalsBloom BurtonReiterated Rating
7/21/2020Fusion PharmaceuticalsJefferies Financial GroupInitiated Coverage
7/21/2020Fusion PharmaceuticalsWedbushInitiated Coverage
7/21/2020Fusion PharmaceuticalsCowenInitiated Coverage
3/30/2021SQZ BiotechnologiesBrookline Capital ManagementReiterated Rating
1/7/2021SQZ BiotechnologiesEvercore ISIInitiated Coverage
11/24/2020SQZ BiotechnologiesStifel NicolausInitiated Coverage
11/24/2020SQZ BiotechnologiesBank of AmericaInitiated Coverage
11/24/2020SQZ BiotechnologiesBTIG ResearchInitiated Coverage
2/17/2021Outlook TherapeuticsLADENBURG THALM/SH SHReiterated Rating
8/27/2020Outlook TherapeuticsHC WainwrightLower Price Target
8/18/2020Outlook TherapeuticsOppenheimerLower Price Target
5/16/2019Outlook TherapeuticsCIBCInitiated Coverage
4/22/2019Outlook TherapeuticsAscendiant Capital MarketsInitiated Coverage
4/7/2021Lineage Cell TherapeuticsChardan CapitalReiterated Rating
3/30/2021Lineage Cell TherapeuticsCantor FitzgeraldInitiated Coverage
3/12/2021Lineage Cell TherapeuticsMaxim GroupReiterated Rating
10/12/2020Lineage Cell TherapeuticsDawson JamesReiterated Rating
9/17/2020Lineage Cell TherapeuticsNoble FinancialInitiated Coverage
11/17/2020OptheaSmith Barney CitigroupInitiated Coverage
11/17/2020OptheaCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
11/11/2020OptheaSVB LeerinkInitiated Coverage
11/11/2020OptheaTruistInitiated Coverage
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.